TNFSF10, TNF superfamily member 10, 8743

N. diseases: 295; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Therapeutic group CTD_human Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. 17718901 2011
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Therapeutic group CTD_human Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. 21209944 2011
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Therapeutic group CTD_human Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. 17636462 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Androgenic protection from TRAIL-induced apoptosis is via enhanced transcription of FLIP in prostate cancer cells/of androgen-sensitivity in androgen-depletion-independent prostate cancer cells/target for therapy of prostate cancer. 18726983 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Based on initial findings that docetaxel-resistant PC3-DR and DU145-DR prostate tumor cell lines express tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptors, we examined whether TRAIL could be used as an alternative method to kill PC3-DR and DU145-DR cells. 18025278 2008
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group BEFREE Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. 17195089 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group LHGDN Apo2L/TRAIL, in combination with low-dose CPT-11 or aphidicolin, induces apoptosis in human prostate cancer cells/with S-phase arrest-inducing drugs may represent promising avenues for its clinical development. 17431115 2007
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Finally, caspase 8 expression levels were as DR5 directly correlated to TRAIL sensitivity in prostate tumor cells. 16541419 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Therapeutic group CTD_human APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy. 16368536 2006
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE More surprisingly, depsipeptide also increased prostate tumor cell sensitivity to TRAIL-induced apoptosis. 15771957 2005
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 AlteredExpression group LHGDN Apo2L/TRAIL, combined with the BH3 mimetic, Bcl-xL inhibitor BH3I-2 ', induced apoptosis synergistically in prostate cancer cells through activation of Caspase-8 and Bid, resulting in activation of Caspase-3 and PARP cleavage. 16215673 2005
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. 12351634 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE Three human prostate tumor cell lines (PC3, DU145 and LNCaP) and their bcl-2-expressing counterparts were tested for their susceptibility to TRAIL. 11439339 2001
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms
0.400 Biomarker group BEFREE These results further define Ad5-TRAIL as a novel anti-tumor therapeutic and demonstrate its potential use as a means for treating prostate tumors, as well as other solid tumors, in vivo. 11545617 2001